Press Release | Sat Nov 10, 2012 9:00am EST

Interim Phase II Data of Merck's Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection to be Presented at the American Association for the Study of Liver Diseases (AASLD) Annual Mee

* Reuters is not responsible for the content in this press release.